Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $27 from $39 and keeps an Outperform rating on the shares. The firm updated its model following the FDA CRL on RGX-121.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio price target lowered to $18 from $25 at Morgan Stanley
- REGENXBIO Faces FDA Setback on RGX-121 Gene Therapy
- Regenxbio price target lowered to $12 from $14 at Goldman Sachs
- Closing Bell Movers: Upwork down over 20% on soft guidance
- Regenxbio price target lowered to $45 from $50 at Clear Street